Moderna Surges On A Second, Unexpected Shot At The Cancer Vaccine Market
Moderna's stock surged after the biotech company partnered with Carsgen to study a new cancer vaccine regimen using mRNA technology, giving Moderna a second opportunity in the field of cancer vaccines.